StockNow
CalendarLog in
U.S. Markets

AbbVie (ABBV) announced positive topline results from the Phase 3 CERVINO study evaluating etentamig in patients with triple-class exposed RRMM; study met its dual primary endpoints

StockNow breaking-news AI analysis

AbbVie announced positive topline results as the Phase 3 CERVINO study evaluating etentamig met its dual primary endpoints in triple-class exposed RRMM patients.

1 stocks
ABBVABBVIE INC.$259.04Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Houthis have launched a large-scale offensive on all fronts along the western coast, according to Sky News Arabia, citing Yemeni military sources

Fed

Fed Governor Waller (Voter) Q&Q: With CPI and PPI in hand, have a pretty accurate view of PCE inflation

Geopolitics

[MARKET UPDATE] Gradual strength in the crude complex has put pressure on the fixed income space, with US equity futures also moving a touch lower; action which lacks a clear driver